Table 3.

Associations of clinical characteristics with QTc ≥ 440 ms in combined SLE/RA cohort

Clinical covariates	Univariable model QTc ≥ 440 ms			Multivariable model QTc ≥ 440 msb
	OR	95% CI	p	OR	95% CI	p
Age	1.02	1.00–1.03	0.004	1.00	0.99–1.02	0.53
Sex	1.29	0.86–1.96	0.22	----------	----------	----------
Race (white vs non-white)	1.48	1.07–2.03	0.016	1.06	0.68–1.63	0.80
Disease duration (square root)	0.96	0.86–1.07	0.48	----------	----------	----------
Current HCQ use	0.48	0.33–0.70	< 0.01	0.77	0.48–1.23	0.27
Current prednisone use	0.46	0.33–0.64	< 0.01	0.56	0.34–0.92	0.023
Current biologic use	0.83	0.58–1.19	0.30	----------	----------	----------
Hypertension	1.18	0.87–1.61	0.29	----------	----------	----------
Current smoking	1.46	0.82–2.60	0.20	----------	----------	----------
Diabetes	1.64	0.95–2.83	0.076	1.38	0.70–2.72	0.35
Current statin use	1.08	0.73–1.60	0.69	----------	----------	----------
Current ASA use	0.51	0.36–0.73	< 0.01	0.68	0.43–1.07	0.095
Any QTc meds	1.07	0.78–1.47	0.67	----------	----------	----------
Antidepressants	1.79	1.07–2.99	0.027	1.45	0.90–2.33	0.12
Antipsychotics	1.62	0.62–4.22	0.33	----------	----------	----------
Antiarrhythmics	1.48	0.43–5.06	0.53	----------	----------	----------
Muscle relaxants	1.41	0.57–3.46	0.46	----------	----------	----------
Antimicrobials	0.99	0.62–1.58	0.97	----------	----------	----------
Antiemetics	1.15	0.63–2.08	0.65	----------	----------	----------
Anticonvulsants	2.33	0.54–1.93	0.94	----------	----------	----------
Tacrolimus	1.63	0.72–3.69	0.24	----------	----------	----------
Ejection fraction %	1.00	0.98–1.03	0.82	----------	----------	----------
Ejection fraction ≥ 55%	0.81	0.44–1.49	0.50	----------	----------	----------
Prob > F	----------			0.0001

Abbreviations: HCQ hydroxychloroquine, QTcMeds QTc prolonging medications

^bFinal imputed data